SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PRCY - ANY BODY HAS ANY NEWS ON THESE

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Joseph Ziebarth who wrote (636)7/10/2000 9:25:18 AM
From: Susan Saline   of 670
 
yeah ... it has been slow for sure ... and one to put on ignore and await the slow forward steps.
or move on to something else.

I dunno why I even bother to hold it sometimes
long since mid 90's with an average of just below 2 dollars

anyways ... some news today ... another step ...

Mon Jul 10 PRCY.OB
New Study Confirms Positive Effects of ProCyte's Patented Copper-Peptide Technology - PR Newswire

biz.yahoo.com

REDMOND, Wash., July 10 /PRNewswire/ -- ProCyte Corporation (OTC Bulletin Board: PRCY - news), a leading skin care and tissue repair company, today announced test results on its Neova(TM) Therapy Cuticle Creme.

The Neova(TM) line of products incorporate ProCyte's patented copper peptide technology that delivers copper peptide in a protected form deep into the surface of the skin. Research has shown that copper is essential to the strength and flexibility of skin. More recent research has demonstrated the importance of copper peptide complexes in wound healing. Neova(TM) anti-aging products, which include moisturizers, lotions and the cuticle creme, deliver copper peptides directly to damaged and worn-out skin, in a natural way that the body recognizes and can use to rebuild itself. The products are specifically formulated to reduce the visible effects of aging, including fine lines and wrinkles.

The evaluation was performed using 15 consumers and 15 nail technicians. The focus of the field test was on damaged cuticle conditions ranging from slightly inflamed, severely dry to cracking and bleeding skin. All evaluations saw an improvement in as little as 3 to 4 days, with over 69% reporting that the Neova(TM) Therapy Cuticle Creme maintained the greatly improved conditions 4 weeks later.

This study confirms and supports a previous skin care study that showed reductions in appearance of fine lines and wrinkles using the Neova(TM) Night Therapy product. The skin care study was a blinded, and placebo controlled study conducted last summer by Dr. James Leyden, a well-respected expert in skin care.

``We are pleased with the results of the new study supporting the positive effects of copper peptides in healing and skin health,'' said Jack Clifford, ProCyte Chairman and CEO. ``ProCyte has established a growing position in the medical marketplace, where demand for our copper peptide therapeutic and anti- aging products has risen dramatically since their launch.''

ProCyte markets its products through its own sales force directly to Dermatologists and Cosmetic Surgeons. The Company also has license and supply agreements in the consumer market with Osmotics and Neutrogena.

About ProCyte:

ProCyte Corporation is a healthcare products company that develops and markets products for skin health, hair care and
wound care. ProCyte's products include a comprehensive therapeutic skin care line including products for post-laser treatment and anti-aging applications, as well as products for thinning hair. Products incorporate ProCyte's patented, clinically proven copper peptide technology, which are marketed both directly and through distribution partners.

This report may contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. This report should be read in conjunction with the Company's annual report on Form 10-K and it's quarterly reports on Form 10-Q. The Company's results may vary significantly from quarter to quarter and will depend, among other factors, on product launches and market acceptance, manufacturing contracts, and distribution agreements.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext